Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine: Leading the Way in Cancer Genomics

September 7th 2012

Siteman patients have access to more than 250 therapeutic clinical trials, and Siteman-affiliated scientists and physicians hold more than $165 million in annual cancer research and related training grants.

Dr. Peter Choyke Discusses Molecular Imaging Research

September 6th 2012

Dr. Peter Choyke, from the National Cancer Institute, Molecular Imaging Program, Discusses Current Molecular Imaging Research.

Vismodegib Effective Against Skin Cancer in Patients With Basal-Cell Nevus Syndrome

August 31st 2012

The oral hedgehog pathway inhibitor vismodegib is effective for both the prevention and treatment of basal-cell carcinoma in patients with the rare disorder known as basal-cell nevus syndrome.

Dr. Scagliotti on Targeted Therapies and Chemotherapy

August 31st 2012

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Dr. Sekulic on the Hedgehog Pathway Inhibitor Vismodegib

August 30th 2012

Dr. Aleksandar Sekulic, from the Mayo Clinic in Arizona, on the Hedgehog Pathway Inhibitor Vismodegib for Basal Cell Carcinoma.

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents

August 30th 2012

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

Targeted Therapies May Have a Role in Urothelial Cancer

August 28th 2012

Pazopanib has demonstrated activity in a majority of patients with refractory urothelial cancer, providing the first evidence that targeted therapies might have a role in the disease.

5 ALK-Related Questions for D. Ross Camidge, MD, PhD and Fredika M. Robertson, PhD

August 27th 2012

Two leading researchers discuss the role of the ALK signaling pathway and development into new ALK-targeted anticancer therapies.

ALK Inhibitors: Moving Rapidly From Discovery to Clinical Approval and Beyond

August 27th 2012

There has been stunning progress as preclinical findings of the ALK gene in patients with lung cancer were rapidly translated into the availability of an FDA-approved therapeutic ALK inhibitor, crizotinib.

Dr. Ribas on MAPK Inhibition With Dabrafenib and Trametinib

August 23rd 2012

Dr. Antoni Ribas, from UCLA Jonsson Comprehensive Cancer Center, on the Benefits of MAPK Inhibition With Dabrafenib and Trametinib

Beyond the Basics: Unique Markers May Assist in Morphologic Classification

August 21st 2012

The presence of specific molecular biomarkers may assist in determining the correct morphologic diagnosis of the particular cancer being examined.

Suzanne Fuqua on Utilizing Predictive Biomarkers

August 21st 2012

Suzanne Fuqua, PhD, from the Baylor College of Medicine, on the Utilization of Predictive Biomarkers

Elaine Mardis on Sensitivity to Aromatase Inhibitors

August 20th 2012

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Exploring Ways to Broaden the Reach of Molecular Tumor Testing

August 17th 2012

The development of targeted therapies for a variety of tumor types has highlighted a greater need for widespread molecular testing to determine which patients have the mutations that these therapies target.

Dr. Herbst Explores Molecular Testing in Lung Cancer

August 15th 2012

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Ranking Value in Cancer Care: Analysis of a "Pathways" Approach

August 13th 2012

Amid a continuing debate over healthcare spending in the United States, the oncology community is growing more introspective about the costs associated with increasingly sophisticated cancer therapeutics.

Dr. Gandara Discusses Molecular Testing for NSCLC

August 9th 2012

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

Tivantinib Achieves Advantage for Patients With HCC

August 9th 2012

Tivantinib has demonstrated statistically significant improvements in time to progression and overall survival versus placebo among patients with unresectable hepatocellular carcinoma.

ASCO Launches Mentor Program With Grant to Noted Researcher

August 8th 2012

An effort to nurture the drug development skills of young oncologists as they explore a novel targeted agent has gained support from the Conquer Cancer Foundation of the American Society of Clinical Oncology.

5 PARP-Related Questions for Melinda L. Telli, MD

August 2nd 2012

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.